Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
For eligible patients, health care providers can send Wegovy prescriptions directly to NovoCare Pharmacy. Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide ...
Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...
March 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash ...
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback